Principal Financial Group Inc. raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 145,775 shares of the company’s stock after buying an additional 2,379 shares during the quarter. Principal Financial Group Inc. owned about 0.17% of IDEXX Laboratories worth $23,531,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Bronfman E.L. Rothschild L.P. raised its stake in IDEXX Laboratories by 2.3% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 770 shares of the company’s stock valued at $119,000 after buying an additional 17 shares during the last quarter. CAPROCK Group Inc. raised its stake in IDEXX Laboratories by 2.2% in the second quarter. CAPROCK Group Inc. now owns 1,830 shares of the company’s stock valued at $295,000 after buying an additional 40 shares during the last quarter. Strs Ohio raised its stake in IDEXX Laboratories by 0.7% in the second quarter. Strs Ohio now owns 5,929 shares of the company’s stock valued at $957,000 after buying an additional 41 shares during the last quarter. Fayez Sarofim & Co raised its stake in IDEXX Laboratories by 1.4% in the first quarter. Fayez Sarofim & Co now owns 3,500 shares of the company’s stock valued at $541,000 after buying an additional 50 shares during the last quarter. Finally, HM Payson & Co. raised its stake in IDEXX Laboratories by 0.4% in the first quarter. HM Payson & Co. now owns 21,091 shares of the company’s stock valued at $3,260,000 after buying an additional 85 shares during the last quarter. Institutional investors own 87.73% of the company’s stock.

A number of equities research analysts have commented on the company. Aegis assumed coverage on IDEXX Laboratories in a research note on Wednesday, May 31st. They issued a “sell” rating and a $118.00 price target for the company. They noted that the move was a valuation call. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $187.00 price target for the company in a research note on Monday, May 29th. BidaskClub upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Stifel Nicolaus reiterated a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a research note on Friday, July 14th. Finally, CL King upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target for the company in a research note on Friday, July 28th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $174.00.

In other news, Chairman Jonathan W. Ayers sold 17,000 shares of the business’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $154.54, for a total value of $2,627,180.00. Following the completion of the sale, the chairman now directly owns 1,039,034 shares of the company’s stock, valued at approximately $160,572,314.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Jonathan W. Ayers sold 13,000 shares of the business’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $150.79, for a total value of $1,960,270.00. Following the completion of the sale, the chairman now directly owns 1,044,034 shares of the company’s stock, valued at $157,429,886.86. The disclosure for this sale can be found here. Insiders have sold a total of 151,734 shares of company stock valued at $23,436,626 over the last ninety days. 2.77% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/12/idexx-laboratories-inc-idxx-shares-bought-by-principal-financial-group-inc.html.

IDEXX Laboratories, Inc. (IDXX) opened at 160.23 on Tuesday. IDEXX Laboratories, Inc. has a one year low of $102.45 and a one year high of $173.01. The stock has a 50 day moving average price of $155.98 and a 200-day moving average price of $158.63. The firm has a market capitalization of $13.98 billion, a price-to-earnings ratio of 55.12 and a beta of 0.49.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.10. The company had revenue of $508.90 million during the quarter, compared to the consensus estimate of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. IDEXX Laboratories’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.74 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.